Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Atopix Therapeutics Awarded Biomedical Catalyst Grant

Published: Thursday, May 30, 2013
Last Updated: Thursday, May 30, 2013
Bookmark and Share
Company awarded £1.7M to study an innovative anti-allergic approach to the treatment of atopic dermatitis.

Atopix Therapeutics Ltd has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).

Atopix has acquired rights to OC459 and other CRTH2 antagonists from Oxagen Ltd. OC459 has successfully completed proof-of-concept clinical trials in asthma and allergic rhinoconjunctivitis. OC459 is a highly potent and selective CRTH2 antagonist which is effective in asthma when given once a day at doses as low as 25 mg.

CRTH2 is a G protein coupled receptor that is selectively expressed by key cell types mediating allergic responses – Th2 lymphocytes, basophils and eosinophils – and is activated by prostaglandin D2, an abundant lipid product of mast cells. Mast cell-dependent activation of Th2 lymphocytes and eosinophils is blocked by CRTH2 antagonists which reduce both allergic sensitisation and effector responses to allergen. The prostaglandin D2/CRTH2 pathway is up-regulated in severe allergic conditions and functional polymorphisms in CRTH2 are associated with asthma and atopic dermatitis.

Atopix now plans to study the effect of once daily treatment with OC459 for 6 months in patients with atopic dermatitis whose condition is poorly controlled by existing therapies. The study is powered to detect an effect on flares, the major health economic burden in atopic dermatitis. The primary endpoint of the study will be the Eczema Activity Severity Index. Atopix will also determine whether functional genetic polymorphisms in CRTH2 influence the therapeutic response to OC459.

The award from the Biomedical Catalyst follows a £3.7 million Series A funding led by MPM Capital, SV Life Sciences and Wellington Partners with additional participation by Bessemer Partners and Red Abbey. In connection with the financing Luke Evnin, Managing Director of MPM Capital, Mike Carter Venture Partner at SV Life Sciences and Regina Hodits, General Partner at Wellington Partners have joined Tim Edwards (Chairman), Mark Payton (CEO), Alan Ezekowitz, CEO and Chairman of Abide Therapeutics and former SVP Respiratory and Immunology franchise at Merck Research Laboratories and Sir John Bell, Regius Professor of Medicine at Oxford University as members of the Board.

Mark Payton, CEO of Atopix, said: “In the past six months, Atopix has transformed itself from a semi-virtual to a fully formed clinical stage biopharmaceutical company. This award from the Biomedical Catalyst, on top of the earlier funding from our key investors, enables us to test this exciting new mechanism for the first time in atopic dermatitis and could provide the first safe, oral, once a day therapy for this disease. Furthermore, since the mechanism is also effective in asthma and allergic rhinitis this would provide a “one-stop” solution for those patients suffering from multiple co-existing allergies, whose only long term alternative at present is multiple topical therapy, usually involving steroids.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!